Valeant Pharmaceuticals's ticker is VRX and the CUSIP is 91911X104. A total of 2 filers reported holding Valeant Pharmaceuticals in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $370,000 | +16.7% | 15,900 | -20.1% | 0.10% | +15.1% |
| Q1 2018 | $317,000 | -23.4% | 19,900 | 0.0% | 0.09% | -23.9% |
| Q4 2017 | $414,000 | +0.2% | 19,900 | -30.9% | 0.11% | -5.0% |
| Q3 2017 | $413,000 | -24.2% | 28,800 | -8.6% | 0.12% | -27.4% |
| Q2 2017 | $545,000 | +61.2% | 31,500 | +2.9% | 0.16% | +54.7% |
| Q1 2017 | $338,000 | – | 30,625 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAXTER BROS INC | 31,500 | $545,000 | 0.16% |
| Sonora Investment Management, LLC | 60 | $1,038,000 | 0.00% |